CAS 2135696-72-7

Formula: C19H18BrClN6O

InChI: InChI=1S/C19H18BrClN6O/c1-27(2)7-3-4-18(28)26-17-9-13-16(10-22-17)23-11-24-19(13)25-12-5-6-15(21)14(20)8-12/h3-6,8-11H,7H2,1-2H3,(H,22,26,28)(H,23,24,25)/b4-3+

InChI key: QBACGOWRJDBXSG-ONEGZZNKSA-N

SMILES: CN(C)C/C=C/C(=O)NC1=NC=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)Cl)Br

Tarlox-TKI

CAS: 2135696-72-7

Tarlox-TKI

Formula: C₁₉H₁₈BrClN₆O

Purity: ≥95%

Molecular weight: 461.74

Ref: 54-BUP21719

Tarlox-TKI

CAS: 2135696-72-7

Purity: 97.03%

Ref: IN-DA01V4I8

Tarlox-TKI

CAS: 2135696-72-7

Tarlox-TKI is a drug with potential anti-cancer activity, which acts as a selective inhibitor of the enzyme P2Y receptor. It binds to the α7 nicotinic acetylcholine receptor, preventing neuronal death and skin cancer. Tarlox-TKI has been shown to inhibit xenograft tumor growth in mice and also suppresses transcriptional regulation of genes involved in autoimmune diseases. Tarlox-TKI interacts with toll-like receptor 4 (TLR4) and inhibits the expression of the gene 2-aminoethoxydiphenyl borate (APBD). Tarlox-TKI prevents p21 from becoming activated by inhibiting polymerase chain reaction (PCR), which leads to inhibition of leukemia inhibitory factor (LIF).

Formula: C₁₉H₁₈BrClN₆O

Purity: Min. 95%

Molecular weight: 461.7 g/mol

Ref: 3D-KKD69672

Tarlox-TKI

CAS: 2135696-72-7

Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.

Formula: C₁₉H₁₈BrClN₆O

Purity: 97.03%

Color and Shape: Solid

Molecular weight: 461.74

Ref: TM-T11761